

Haemonetics acquisition delayed by FDA setback

Published on Medical Design Technology (<http://www.mdtmag.com>)

Haemonetics acquisition delayed by FDA setback

Mass High Tech: The Journal of New England Technology

Haemonetics (NYSE: HAE), a blood management company, must delay the closing of its acquisition of Hemerus Medical, after the U.S. Food and Drug Administration delayed approval of a Hemerus product. The acquisition is contingent on the FDA approval.

Source URL (retrieved on 02/27/2015 - 1:06am):

http://www.mdtmag.com/news/2012/09/haemonetics-acquisition-delayed-fda-setback?qt-recent_content=0&qt-video_of_the_day=0